We are testing a new treatment combining Mosunetuzumab and Venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia. The goal is to evaluate its safety and effectiveness compared to Mosunetuzumab alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of abnormal lymphocytes. It can be relapsed or refractory, meaning it may return after treatment or not respond to it.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
